1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- ADDMEDICA
- Bristol-Myers Squibb
- Emmaus Medical
- Novartis
- Pfizer
- MORE
Strong pipeline of drugs to drive market growth. The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the late stages of clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies. Thus, helping the vendors with quick development of these drugs. The analysts have predicted that the sickle cell disease treatment market will register a CAGR of over 11% by 2023.
Market Overview
High prevalence of sickle cell disease
The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.
Lack of approved therapies
Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.
For the detailed list of factors that will drive and challenge the growth of the sickle cell disease treatment market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer, the competitive environment is quite intense. Factors such as the high prevalence of sickle cell disease and the strong pipeline of drugs, will provide considerable growth opportunities to sickle cell disease treatment manufactures. ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer are some of the major companies covered in this report.
Market Overview
High prevalence of sickle cell disease
The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.
Lack of approved therapies
Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.
For the detailed list of factors that will drive and challenge the growth of the sickle cell disease treatment market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer, the competitive environment is quite intense. Factors such as the high prevalence of sickle cell disease and the strong pipeline of drugs, will provide considerable growth opportunities to sickle cell disease treatment manufactures. ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- ADDMEDICA
- Bristol-Myers Squibb
- Emmaus Medical
- Novartis
- Pfizer
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Indication - Market share 2018-2023 (%)
Exhibit 18: Comparison by indication
Exhibit 19: Sickle cell anemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Sickle cell anemia - Year-over-year growth 2019-2023 (%)
Exhibit 21: Sickle beta thalassemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Sickle beta thalassemia - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Gene therapy pipeline for sickle cell
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ADDMEDICA - Vendor overview
Exhibit 47: ADDMEDICA - Business segments
Exhibit 48: ADDMEDICA - Organizational developments
Exhibit 49: ADDMEDICA - Key offerings
Exhibit 50: ADDMEDICA - Key customers
Exhibit 51: Bristol-Myers Squibb - Vendor overview
Exhibit 52: Bristol-Myers Squibb - Business segments
Exhibit 53: Bristol-Myers Squibb - Organizational developments
Exhibit 54: Bristol-Myers Squibb - Geographic focus
Exhibit 55: Bristol-Myers Squibb - Key offerings
Exhibit 56: Bristol-Myers Squibb - Key customers
Exhibit 57: Emmaus Medical - Vendor overview
Exhibit 58: Emmaus Medical - Business segments
Exhibit 59: Emmaus Medical - Organizational developments
Exhibit 60: Emmaus Medical - Geographic focus
Exhibit 61: Emmaus Medical - Key offerings
Exhibit 62: Emmaus Medical - Key customers
Exhibit 63: Novartis - Vendor overview
Exhibit 64: Novartis - Business segments
Exhibit 65: Novartis - Organizational developments
Exhibit 66: Novartis - Geographic focus
Exhibit 67: Novartis - Segment focus
Exhibit 68: Novartis - Key offerings
Exhibit 69: Novartis - Key customers
Exhibit 70: Pfizer - Vendor overview
Exhibit 71: Pfizer - Business segments
Exhibit 72: Pfizer - Organizational developments
Exhibit 73: Pfizer - Geographic focus
Exhibit 74: Pfizer - Segment focus
Exhibit 75: Pfizer - Key offerings
Exhibit 76: Pfizer - Key customers
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by indication
- Comparison by indication
- Sickle cell anemia - Market size and forecast 2018-2023
- Sickle beta thalassemia - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by indication
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ADDMEDICA
- Bristol-Myers Squibb
- Emmaus Medical
- Novartis
- Pfizer
- Research methodology
- List of abbreviations
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Indication - Market share 2018-2023 (%)
Exhibit 18: Comparison by indication
Exhibit 19: Sickle cell anemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Sickle cell anemia - Year-over-year growth 2019-2023 (%)
Exhibit 21: Sickle beta thalassemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Sickle beta thalassemia - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Gene therapy pipeline for sickle cell
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ADDMEDICA - Vendor overview
Exhibit 47: ADDMEDICA - Business segments
Exhibit 48: ADDMEDICA - Organizational developments
Exhibit 49: ADDMEDICA - Key offerings
Exhibit 50: ADDMEDICA - Key customers
Exhibit 51: Bristol-Myers Squibb - Vendor overview
Exhibit 52: Bristol-Myers Squibb - Business segments
Exhibit 53: Bristol-Myers Squibb - Organizational developments
Exhibit 54: Bristol-Myers Squibb - Geographic focus
Exhibit 55: Bristol-Myers Squibb - Key offerings
Exhibit 56: Bristol-Myers Squibb - Key customers
Exhibit 57: Emmaus Medical - Vendor overview
Exhibit 58: Emmaus Medical - Business segments
Exhibit 59: Emmaus Medical - Organizational developments
Exhibit 60: Emmaus Medical - Geographic focus
Exhibit 61: Emmaus Medical - Key offerings
Exhibit 62: Emmaus Medical - Key customers
Exhibit 63: Novartis - Vendor overview
Exhibit 64: Novartis - Business segments
Exhibit 65: Novartis - Organizational developments
Exhibit 66: Novartis - Geographic focus
Exhibit 67: Novartis - Segment focus
Exhibit 68: Novartis - Key offerings
Exhibit 69: Novartis - Key customers
Exhibit 70: Pfizer - Vendor overview
Exhibit 71: Pfizer - Business segments
Exhibit 72: Pfizer - Organizational developments
Exhibit 73: Pfizer - Geographic focus
Exhibit 74: Pfizer - Segment focus
Exhibit 75: Pfizer - Key offerings
Exhibit 76: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- ADDMEDICA
- Bristol-Myers Squibb
- Emmaus Medical
- Novartis
- Pfizer
- MORE
Global Sickle Cell Disease Treatment Market 2019-2023
The author recognizes the following companies as the key players in the global sickle cell disease treatment market: ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strong pipeline of drugs.”
According to the report, one of the major drivers for this market is the high prevalence of sickle cell disease.
Further, the report states that one of the major factors hindering the growth of this market is the lack of approved therapies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author recognizes the following companies as the key players in the global sickle cell disease treatment market: ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strong pipeline of drugs.”
According to the report, one of the major drivers for this market is the high prevalence of sickle cell disease.
Further, the report states that one of the major factors hindering the growth of this market is the lack of approved therapies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- ADDMEDICA
- Bristol-Myers Squibb
- Emmaus Medical
- Novartis
- Pfizer
Note: Product cover images may vary from those shown
